![Simon Allen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Simon Allen
Net worth: - $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Sonja Nelson | F | 51 |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 3 years |
Daniel George | M | 54 | 1 years | |
Ying Buechler | M | - | 6 years | |
Bimal Shah | M | 48 | 1 years | |
Richard Cunningham | M | 54 | 1 years | |
Nathaniel Calloway | M | 42 | 2 years | |
Kenneth Cundy | M | 65 | 2 years | |
Jakob Dupont | M | 58 | 3 years | |
Xiaowei Chang | M | 41 | 9 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Katrin Rupalla | M | 56 |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Philippe Calais | M | 65 | 2 years | |
Lawson Macartney | M | 66 | 2 years | |
Rex Merchant | M | 64 | 2 years | |
Olivia Ware | F | 67 |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Christian Nolet | M | 67 |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | - |
Christopher Fuglesang | M | 56 | 4 years | |
Crispina Calsada | F | 54 | 11 years | |
Steven Schoenfeld | M | - |
CovX Research LLC
![]() CovX Research LLC BiotechnologyHealth Technology Part of Pfizer Inc., CovX Research LLC is a company that manufactures biotherapeutics and medical products. The company is based in San Diego, CA. The company was founded by Richard Alan Lerner, Carlos F. Barbas. CovX Research was acquired by Pfizer Inc. from Tavistock Life Sciences Co. on January 31, 2008 for $230 million. | 3 years |
Tiecheng Qiao | M | - | - | |
Sheila Gujrathi | M | 53 | 1 years | |
Marc Goldberg | M | 67 | 4 years | |
Xiao Le | M | 34 |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | - |
Eric Bjerkholt | M | 64 | - | |
Gary Yeung | M | - | - | |
Daniel Schneeberger | M | 40 | 2 years | |
Elias Bendekgey | M | 66 |
Nuvelo, Inc.
| 5 years |
Barry Greene | M | 60 | - | |
Joy Yan | M | 44 |
Ambrx Biopharma, Inc.
![]() Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | - |
Deanna Weber | F | - | 12 years | |
Yong Jiang Hei | M | 61 | 3 years | |
Mark P. Joing | M | 52 |
Nuvelo, Inc.
| 5 years |
Linda Klumpers | M | - | - | |
Yi Gu | M | 55 | 2 years | |
Pratik Multani | M | 57 |
Kalypsys, Inc.
![]() Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | 2 years |
Julia Brown | F | 76 |
CovX Research LLC
![]() CovX Research LLC BiotechnologyHealth Technology Part of Pfizer Inc., CovX Research LLC is a company that manufactures biotherapeutics and medical products. The company is based in San Diego, CA. The company was founded by Richard Alan Lerner, Carlos F. Barbas. CovX Research was acquired by Pfizer Inc. from Tavistock Life Sciences Co. on January 31, 2008 for $230 million. | 4 years |
John W. Wallen | M | 66 | 10 years | |
Martin Vogelbaum | M | 60 |
Nuvelo, Inc.
| 8 years |
Sandra Gardiner | F | 58 | - | |
Barry Zubrow | M | 70 |
Nuvelo, Inc.
| 3 years |
Peter G. Schultz | M | 67 | 10 years | |
Burton E. Sobel | M | 86 |
Nuvelo, Inc.
| 5 years |
Thomas N. McCarter | M | 93 |
Nuvelo, Inc.
| 8 years |
Peter García | M | 62 |
Nuvelo, Inc.
| 3 years |
Michael D. Levy | M | 63 |
Nuvelo, Inc.
| 4 years |
Jan Johansson | M | - |
Nuvelo, Inc.
| 1 years |
Linda Fitzpatrick | F | 67 |
Nuvelo, Inc.
| 4 years |
Kim Popovits | F | 65 |
Nuvelo, Inc.
| 4 years |
Peter Kiener | M | 72 | 1 years | |
Steven R. Deitcher | M | 59 |
Nuvelo, Inc.
| 3 years |
Alan F. Wahl | M | - | - | |
Luis Peña | M | 61 |
Nuvelo, Inc.
| 4 years |
S. Michael Imperiale | M | - |
Nuvelo, Inc.
| 3 years |
Sukumar Sakamuri | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 53 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Simon Allen
- Personal Network